Hepatic ischemia/reperfusion (I/R) injury is an inflammation-mediated process arising from ischemia/reperfusion-elicted stress in multiple cell types, causing liver damage during surgical procedures and often resulting in liver failure. Endoplasmic reticulum (ER) stress triggers the activation of the unfolded protein response (UPR) and is implicated in tissue injuries, including hepatic I/R injury. However, the cellular mechanism that links the UPR signaling to local inflammatory responses during hepatic I/R injury remains largely obscure. Here, we report that IRE1α, a critical ER-resident transmembrane signal transducer of the UPR, plays an important role in promoting Kupffer-cell-mediated liver inflammation and hepatic I/R injury. Utilizing a mouse model in which IRE1α is specifically ablated in myeloid cells, we found that abrogation of IRE1α markedly attenuated necrosis and cell death in the liver, accompanied by reduced neutrophil infiltration and liver inflammation following hepatic I/R injury. Mechanistic investigations in mice as well as in primary Kupffer cells revealed that loss of IRE1α in Kupffer cells not only blunted the activation of the NLRP3 inflammasome and IL-1β production, but also suppressed the expression of the inducible nitric oxide synthase (iNos) and proinflammatory cytokines. Moreover, pharmacological inhibition of IRE1α’s RNase activity was able to attenuate inflammasome activation and iNos expression in Kupffer cells, leading to alleviation of hepatic I/R injury. Collectively, these results demonstrate that Kupffer cell IRE1α mediates local inflammatory damage during hepatic I/R injury. Our findings suggest that IRE1α RNase activity may serve as a promising target for therapeutic treatment of ischemia/reperfusion-associated liver inflammation and dysfunction.

Hepatic ischemia/reperfusion (I/R) injury represents one of the major complications occurring during liver resection, transplantation, hypovolemic shock, and other liver surgeries, which causes increased risk of organ rejection and liver dysfunction (1–3). Hepatic I/R injury is viewed as a dynamic two-phase process that involves local ischemic stress and inflammation-mediated reperfusion damage in the liver (1, 2, 4–6). Hepatic I/R injury is initiated by the ischemic insult that leads to cellular damage and cell death of hepatocytes via oxidative stress and reactive oxygen species (ROS) production, triggering a local sterile immune response characterized by recruitment of Kupffer cells (KCs) and neutrophils. Propagation of the innate and adaptive immune responses in turn results in elevated cytokine production, further aggravating hepatocyte cell death and necrotic damage in the liver (1, 6, 7). Many intracellular signaling cascades in multiple cell types in the liver, including hepatocytes and immune cells as well, have been implicated in the mechanisms underlying the inflammation-mediated injury as a result of the ischemia/reperfusion-elicted stress (1–6, 8, 9). For instance, emerging evidence indicates that KCs, the liver-resident specialized macrophages (10, 11), play crucial roles in orchestrating the initial innate immune responses through phagocytosing necrotic cells, producing proinflammatory cytokines, and recruiting other inflammatory cells including neutrophils and circulating monocytes, thus driving local inflammation in the liver upon I/R injury (4–7, 12). Moreover, it has been documented that the nucleotide-binding domain, leucine-rich repeat containing protein 3 (NLRP3) critically contributes to the sterile inflammatory response and liver damage during hepatic I/R injury, either through activation of inflammasome in KCs (4–6) or via affecting the recruitment of neutrophils (6, 13). In addition, inducible nitric oxide synthase (iNos), a cytokine-regulated enzyme that converts L-Arginine to L-Citrulline and nitric oxide (NO) in many types of cells including immune cells such as macrophages (14–17), has been documented to be involved in inflammation-mediated tissue injury, while its exact roles in hepatic I/R injury have been controversial (18–20). Importantly, hepatic I/R injury remains to be a clinically unsolved problem lacking effective intervention strategies. Therefore, it is of particular translational significance to improve our understanding of the
Kupffer cell IRE1α promotes hepatic I/R injury

Endoplasmic reticulum (ER) stress is instigated by increased accumulation of unfolded/misfolded proteins in the ER lumen. ER stress activates the cellular unfolded protein response (UPR) regulated by three ER-resident transmembrane signal transducers, inositol-requiring enzyme 1 (IRE1), protein kinase RNA-like endoplasmic reticulum kinase (PERK), and activating transcription factor 6 (ATF6). IRE1 is the most evolutionarily conserved ER stress sensor that contains the Ser/Thr protein kinase and endoribonuclease (RNase) activities within its cytoplasmic portion. Upon ER stress, IRE1 is activated through autophosphorylation and dimerization/oligomerization and catalyzes the unconventional splicing of the mRNA encoding the transcription factor X-box binding protein 1 (XBP1) or degrades selected mRNA species in a process referred to as “regulated IRE1-dependent decay” (RIDD). ER stress has been implicated in various pathological conditions, including obesity, type 2 diabetes, cancer, as well as liver diseases. Reported studies have also revealed that the ER stress response is activated during hepatic I/R injury, with distinct biphasic activation of the UPR branches found at the two stages of hepatic I/R injury (34). It is also notable that in mouse models, IRE1α appears to be involved in exerting a protective action from ER stress preconditioning or an aggravating effect from high-fat diet-induced fatty liver upon hepatic I/R injury (38, 39). However, the precise cellular mechanisms that link individual UPR branches to inflammatory liver damage remain largely obscure.

The IRE1α branch plays a critical role in regulating macrophage activation and inflammatory cytokine production under a variety of stress conditions. Given its involvement in regulating macrophage inflammasome activation as well as its polarized activation states during metabolic inflammation, we wondered if IRE1α also acts to regulate the immune responses of KCs during hepatic I/R injury. In this study, we utilized the mouse model in which IRE1α is specifically ablated in myeloid cells and investigated whether IRE1α in KCs contributes to inflammatory liver damage. We found that IRE1α in KCs mediates inflammasome activation and drives iNOS expression, thus promoting hepatic I/R injury in a manner that depends on its RNase activity.

Results

Activation of the IRE1α pathway and NLRP3 inflammasome in Kupffer cells during hepatic I/R injury

To investigate whether the UPR signaling branch is implicated in KC activation in response to hepatic I/R injury, we established the hepatic I/R injury model in mice that were subjected to 60 min of partial warm ischemia followed by 6 h of reperfusion in the liver. Immunoblot analyses revealed elevations in IRE1α phosphorylation as well as in the spliced form of XBP1 (XBP1s) protein level, but no apparent changes in eIF2α phosphorylation in I/R-injured livers relative to their sham control. In line with previously reported studies, we observed robust increases in NLRP3 and cleaved Caspase 1 (c-Casp1) proteins in I/R-injured livers. This indicates marked activation of NLRP3 inflammasome, a multiprotein platform that is assembled to activate Caspase 1 for the maturation and release of the proinflammatory cytokine IL-1β.

Next, we examined the UPR and inflammasome activation in KCs and hepatocytes that were freshly isolated from the livers of mice following I/R injury or sham control. Whereas more prominently increased IRE1α phosphorylation was detected in KCs than in hepatocytes from the livers after I/R injury, higher expression levels of XBP1s protein were seen in both cell types. Consistently, no increases in eIF2α phosphorylation were detected in KCs or hepatocytes. Remarkably, marked elevations in NLRP3 and c-Casp1 proteins were observed in KCs but not in hepatocytes from I/R-injured livers. Moreover, quantitative RT-PCR profiling analyses showed significantly higher levels of Xbp1s mRNA along with its transcriptional target gene Erdi4 in both KCs and hepatocytes from I/R-injured livers. In parallel, significant elevations in the expression of proinflammatory genes were detected in KCs, including Ccl2, Il1b, Il6 as well as Nos2, while only Ccl2 expression was higher in hepatocytes following I/R injury. These data suggest that the IRE1α branch of the UPR can be selectively activated, which is accompanied by NLRP3 inflammasome activation, in KCs, the main cell type mediating hepatic inflammation during I/R injury.

Myeloid IRE1α ablation results in alleviation of I/R-induced hepatic injury and inflammation

To determine whether IRE1α activation in KCs contributes to hepatic I/R injury, we used the mouse model in which the Ern1 gene (encoding IRE1α) is specifically abrogated in myeloid cells (MΦKO) by intercrossing the Ern1-flox/flox mice with the Lysozyme2-Cre line. As expected, immunoblot analysis showed that IRE1α protein expression was completely abolished in KCs but not in hepatocytes of MΦKO mice in comparison with flox/flox control animals, which led to an efficient reduction in Xbp1s mRNA level specifically in KCs with or without I/R injury. However, IRE1α abrogation did not result in alterations in the mRNA expression of typical UPR genes, such as Atf4, Bip, or Chop, either in KCs or in hepatocytes. Relative to their control counterparts, MΦKO mice exhibited significantly less hepatic necrotic area, lower serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, and decreased cell death in their livers following hepatic I/R procedure. Moreover, immunostaining assessment showed that loss of IRE1α led to significant reductions in Ly6G+ neutrophil infiltration induced by hepatic I/R injury in the livers of MΦKO mice relative to their sham controls. In parallel, significantly lower serum levels of proinflammatory cytokines/chemokines were detected in
MΦKO animals following hepatic I/R injury, including IL-1β, CCL2, TNFα, and CXCL10 (Fig. 3B). Interestingly, significantly reduced mRNA expression levels of Ccl2 and Nos2 (encoding iNos protein), but not Il1b, were observed in KCs isolated from I/R-injured MΦKO livers (Fig. 3C), whereas no significant reduction in Ccl2, Il1b or Nos2 expression was seen in their hepatocytes (Fig. 3D).

To further affirm that KCs, which constitute a major portion of liver-resident macrophages (53), mediated the observed alleviating effects of IRE1α deficiency upon hepatic I/R injury in MΦKO mice, we used clodronate liposomes that can selectively deplete tissue-resident macrophages (e.g., KCs) but not neutrophils through induction of apoptosis (54). Indeed, treatment with clodronate liposomes, but not the vehicle control, could efficiently deplete liver F4/80+ macrophages in mice (Fig. 4A) and resulted in significantly lower serum ALT and AST levels (Fig. 4B), less hepatic necrotic area (Fig. 4C), decreased liver cell death (Fig. 4D), and
reductions in Ly6G+ neutrophil infiltration (Fig. 4E) as well as serum levels of proinflammatory cytokines/chemokines (Fig. 4F) in control mice following hepatic I/R injury. However, we observed no further alleviating effects from clodronate treatment in I/R-injured MΦKO mice (Fig. 4, B–F), suggesting that the impact of IRE1α upon hepatic I/R injury was primarily mediated by its actions in liver macrophages, particularly KCs, rather than other myeloid cells such as neutrophils. Together, these results demonstrate that IRE1α deficiency in KCs protects mice against hepatic I/R injury, indicating a role for IRE1α in KCs in mediating the inflammatory responses to promote hepatic I/R injury.

**IRE1α in Kupffer cells regulates the activation of NLRP3 inflammasome in a RNase activity-dependent manner**

Next, we asked if IRE1α abrogation influenced NLRP3 inflammasome activation in KCs during hepatic I/R injury, thereby leading to lower protein production of IL-1β instead of affecting its mRNA transcription. Indeed, immunoblot
analyses showed significant attenuation of I/R injury-induced elevations in NLRP3 protein and Caspase 1 cleavage (c-Casp1) from MΦKO livers relative to their flox/flox control counterparts (Fig. 5A). Consistently, we observed that in isolated KCs but not in hepatocytes, loss of IRE1α resulted in marked reduction of XBP1s protein without affecting eIF2α phosphorylation, in parallel with lower NLRP3 protein level and more prominently reduced c-Casp1 protein level (Fig. 5B). To further investigate how IRE1α is involved in regulating NLRP3 in inflammasome, we treated primary KCs with LPS and nigericin (NG) to fully activate NLRP3 inflammasome and IL-1β maturation (55). Whereas LPS alone could increase both XBP1s and NLRP3 protein expression levels without inducing c-Casp1 or secreted IL-1β production, LPS plus NG treatment resulted in a higher level of IRE1α phosphorylation and strongly increased c-Casp1 protein level as well as IL-1β production (Fig. 6, A and B). Interestingly, IRE1α deficiency had no significant impact upon NLRP3 protein expression but robustly blunted LPS/NG-induced Caspase 1 cleavage and IL-1β production in MΦKO KCs (Fig. 6, A and B). Then, we used 4µ8C, a specific chemical inhibitor of IRE1α’s RNase activity (56, 57), which could effectively block XBP1s protein expression (Fig. 6C). Remarkably, 4µ8C inhibition of IRE1α RNase resulted in significant suppression of c-Casp1 protein and secreted IL-1β production in LPS/NG-stimulated KCs without affecting NLRP3 protein expression level (Fig. 6, C and D). These data suggest that IRE1α acts through its RNase activity to promote the activation of NLRP3 inflammasome assembly in KCs, thus driving IL-1β maturation/secretion during hepatic I/R injury. Given the observed decrease of NLRP3 protein in MΦKO KCs from I/R-injured livers, it is likely that other factors or

Figure 3. Myeloid IRE1α deficiency leads to suppression of liver inflammation upon I/R injury. MΦKO or Ern1-flox/flox control mice were subjected to sham or hepatic warm ischemia/reperfusion (n=3–4 per group). A, immunohistochemical staining of Ly6G+ neutrophils in liver sections of the indicated group. Quantification of Ly6G+ cells per field is shown. Scale bar, 100 μm. B, ELISA analysis of serum levels of the indicated inflammatory cytokines. C and D, qRT-PCR analysis of mRNA abundance of indicated inflammatory genes in freshly isolated Kupffer cells (C) or hepatocytes (D). All data represent the mean ± SD. *p < 0.05 and **p < 0.01 by two-way ANOVA.
Kupffer cell IRE1α promotes hepatic I/R injury

Figure 4. Depletion of liver macrophages diminished the alleviating effects of IRE1α deficiency upon hepatic I/R injury. MΦKO or Ern1-flox/flox control mice were treated through tail-vein injection with clodronate liposomes (Clod) or vehicle liposomes (200 μl per mouse). Animals were then subjected to sham or hepatic warm ischemia/reperfusion (n=3–4 per group). A, representative images showing clodronate depletion of F4/80+ macrophages in liver sections of mice. Scale bar=15 μm. B, serum ALT and AST levels in mice of the indicated groups. C, representative images of TUNEL staining of liver sections. TUNEL-positive cells per field were quantified. Scale bar=15 μm. D, immunohistochemical staining of Ly6G+ neutrophils in liver sections. Quantification of Ly6G+ cells per field is shown. Scale bar=100 μm. E, ELISA analysis of serum levels of the indicated inflammatory cytokines. All data represent the mean ± SD. *p < 0.05, **p < 0.01, and ***p < 0.001 by two-way ANOVA.

additional mechanisms are involved in IRE1α regulation in vivo of NLRP3 inflammasome.

IRE1α RNase in Kupffer cells promotes iNos expression during hepatic I/R injury

Because iNos is a key inflammatory mediator implicated in exacerbating liver dysfunction during I/R injury (18–20), we investigated whether iNos expression in KCs also behaved as a downstream effector in mediating IRE1α regulation of inflammatory damage. Indeed, immunoblot analyses revealed a marked reduction in I/R injury-induced iNos protein in MΦKO livers relative to their flox/flox counterparts (Fig. 7A), and IRE1α ablation led to dramatic decreases in the upregulation of Nos2 mRNA as well as iNos protein expression in isolated KCs following I/R injury (Fig. 7, B and C). Furthermore, chronic LPS treatment could prominently and dose-dependently stimulate the iNos protein as well as Nos2 mRNA expression, and loss of IRE1α markedly blunted it (Fig. 7, D–G). This is in line with our previous observation that IRE1α is crucial for LPS-induced iNos expression in bone-marrow-derived macrophages (42). In addition, inhibition by 4μ8C of IRE1α’s RNase activity also decreased LPS-stimulated iNos protein expression in primary KCs (Fig. 7H). These results indicate that IRE1α RNase-dependent regulation of iNos may also contribute to hepatic I/R injury. It is very likely that IRE1α could promote the expression of iNos through its UPR effector XBP1s, which has been documented to drive its transcription in cultured HepG2 cell line under experimental ER stress (58) or in mouse astrocytes during chemical-induced neuroinflammation (59).

Pharmacological inhibition of IRE1α RNase activity protects mice against hepatic I/R injury

Given that IRE1α acts through its RNase activity to promote NLRP3 inflammasome activation and iNos expression in KCs, we tested the pharmacologic effects of 4μ8C upon I/R-induced liver inflammation and injury in mice. To this end, administration of 4μ8C in I/R injured animals significantly reduced hepatic necrotic area, lowered their serum levels of ALT and AST, and decreased cell death in livers when compared with the vehicle control group (Fig. 8, A–C). Moreover, 4μ8C-treated animals exhibited significant reductions in liver infiltration of Ly6G+ neutrophils and in serum levels of proinflammatory cytokines/chemokines, including IL-1β, TNFa, CCL2, and CXCL10 (Fig. 9, A and B). Similar to the observations in MΦKO livers, 4μ8C inhibition of IRE1α RNase in I/R-injured mice resulted in decreased Xbp1s and Erdj4 mRNA levels without affecting the expression of other UPR target genes (Bip, Chop, Atf4) in isolated KCs, in parallel with lower Nos2 and Ccl2, but not Il1b, mRNA levels (Fig. 9, C and D). Notably, 4μ8C inhibited the IRE1α-XBP1s pathway, but did not significantly suppress the expression of inflammatory cytokines examined in isolated hepatocytes (Fig. S2). Consistently, immunoblot analyses showed that 4μ8C treatment reduced XBP1s protein production without altering eIF2α phosphorylation and led to significant decreases in NLRP3, c-Casp1, and iNos protein levels (Fig. 9F). Supporting the functional significance of 4μ8C suppression of iNos expression, administration of 1400W, a chemical iNos enzyme inhibitor (60), largely phenocopied the alleviating effects of the IRE1α inhibitor upon I/R-induced liver dysfunction and inflammation in mice (Fig. S3). Collectively, these results indicate that pharmacologically blocking the RNase activity of
IRE1α can limit Kupffer-cell-mediated liver inflammation and damage during hepatic I/R injury.

Discussion
As a common clinical issue resulting from various surgical procedures such as liver transplantation and hepatic resection, hepatic I/R injury can cause graft dysfunction and liver failure (12) and currently lacks effective therapeutic approaches. Validated pharmacologic targets are urgently needed for the development of novel clinical strategy to improve the outcomes of liver surgeries. Liver inflammation is a key feature of hepatic I/R injury, and multiple types of immune cells are involved in mediating the inflammatory damage in response to I/R-induced stress. In this study, we demonstrated a critical role for IRE1α in exacerbating hepatic I/R injury through promoting Kupffer-cell-mediated liver inflammatory responses. Importantly, we found that pharmacologic inhibition of IRE1α RNase activity could efficiently dampen liver inflammation and alleviate hepatic I/R injury in mice. Our findings suggest that IRE1α in KCs represents a promising target for developing therapeutics for the prevention and treatment of IR-associated liver dysfunction.

Numerous studies have established that IRE1α serves as a multifunctional signal transducer in managing cellular stress responses and regulating diverse biological processes including cell fate decision, proliferation, metabolism, and immunity (22, 24–26, 29, 30). Upon activation, IRE1α exerts its regulatory actions mainly through its RNase activity-directed XBP1s production or RIDD control of select mRNA/microRNA stability (24–26, 29, 30). In accordance with its role in governing myeloid cell activation during inflammatory responses (41–43), our results revealed that IRE1α can augment the activation of KCs, presumably in response to hepatic danger-associated molecular pattern (DAMP) molecules generated under I/R-induced stress conditions (61). Mechanistically, IRE1α employs its RNase activity to promote NLRP3 inflammasome activation for IL-1β.
production along with upregulation of iNos expression, which can collectively amplify liver inflammation to cause liver injury (6, 12, 61). Moreover, we found that IRE1α deficiency appeared to cause decreased protein level of NLRP3 in isolated primary KCs following I/R injury, but had no impact upon NLRP3 protein in LPS/NG-stimulated KCs. While this conceivably reflects the effects in vivo of other factors/cell types from the disrupted liver microenvironment inflicted by the I/R stress, it is likely that IRE1α in KCs mainly acts to promote the assembly of NLRP3 inflammasome in a manner that depends on its RNase activity. This is in line with reported findings that IRE1α is linked to inflammasome activation through thioredoxin-interacting protein (TXNIP), a promoting molecule in oxidative-stress-associated inflammasome activation (62), in other cell types, or upon stimulation by other stress stimuli (46, 63, 64). In addition, reported studies have also shown that XBP1 is implicated in the regulation by myeloid heat shock transcription factor 1 (HSF1)-β-catenin signaling of NLRP3 inflammasome activation during I/R injury in the liver (46), and β-catenin can interact with XBP1s in the context of hypoxia response (65). Given the complex mechanisms governing inflammasome assembly/activation in relation to mitochondrial damage and intracellular lipid flux during ischemic stress, it remains to be further dissected whether TXNIP or XBP1s is directly involved in IRE1α-mediated inflammasome activation in KCs during I/R injury. In addition, the NLRP3 inflammasome is a critical sensor and mediator of the inflammatory response, which can be activated by a variety of external stimuli and regulated by many interrelated cellular pathways (62). Other, probably IRE1α-independent, signaling pathways may also be involved in activation of the NLRP3 inflammasome, e.g., the NF-κB signaling (62) or PERK (46, 63, 64) pathways during ischemic stress. Interestingly, in an NLRP3 knockout mouse model, NLRP3 was shown to regulate chemokine-mediated functions and recruitment of neutrophils, thereby contributing to hepatic I/R injury independently of inflammasomes (6, 13). Therefore, it warrants further investigation whether IRE1α is also implicated in other NLRP3-related process.

It is worth noting that IRE1α also acts through its RNase activity to augment the expression of iNos in KCs, most likely in a similar fashion depending upon its downstream effector XBP1s as documented in other cell types (58, 59). Despite the controversial findings with regard to the role of iNos in hepatic I/R injury from genetic deletion studies (18–20), we found that pharmacologic blocking of iNos activity in mice with a selective iNos inhibitor 1400W could efficiently improve liver I/R injury. Importantly, the beneficial effects of 4μ8C inhibition of
IRE1α RNase in mice upon hepatic I/R injury are accompanied by significant suppression of NLRP3 inflammasome activation as well as iNos expression in KCs. Therefore, there results support that multiple players, including both inflammasome activation and iNos upregulation, contribute to mediating IRE1α’s promoting effects upon liver I/R injury. Given that liver I/R is a dynamic process involving many cell types in eliciting sterile inflammation and hepatocyte damage (1, 2, 6, 66), we cannot exclude the potential, either direct or indirect, impacts of IRE1α deletion or its RNase inhibition upon recruitment and activation of other immune cells such as infiltrated monocytes/macrophages as exemplified by reported studies (26, 42, 43, 46, 67). Moreover, we have previously shown that in hepatocytes, IRE1α not only regulates nutrient

Figure 7. IRE1α deficiency diminishes iNos expression in Kupffer cells. A–C, control or M0KO mice were subjected to sham or hepatic warm ischemia/reperfusion (n=3–4 per group). A, immunoblot analysis of iNos protein in liver lysates. β-Actin was used as the loading control. B, qRT-PCR analysis of the mRNA abundance of Nos2 in isolated Kupffer cells. C, immunoblot analysis of iNos protein in freshly isolated Kupffer cells. HSP90 was used as the loading control. The relative levels of iNos protein were quantified. D–G, Kupffer cells were isolated from control and M0KO mice. Cells were then treated with 100 ng/ml LPS for the indicated time intervals (D and E), or with 0.1 or 1 μg/ml LPS for 12 h (F and G). D and F, immunoblot analysis of IRE1α and iNos protein. E and G, qRT-PCR analysis of the mRNA abundance of Xbp1s and Nos2. H, primary Kupffer cells were treated with PBS (veh) or 100 ng/ml LPS with or without 10 μM 4μ8C. Immunoblot analysis of the indicated proteins. The relative levels of iNos protein were quantified. All data represent the mean ± SD. *p < 0.05, **p < 0.01, and ***p < 0.001 by one way or two-way ANOVA.
stress responses but also drives reparative regeneration and obesity-associated liver inflammation (68–71). Thus, it has yet to be further investigated if hepatocyte IRE1 α also contributes to sterile inflammation and hepatocyte damage during hepatic I/R injury.

In conclusion, our current study has revealed that KC IRE1 α responds to ischemic stress and promotes liver inflammatory injury caused by I/R. Targeted inhibition of the IRE1 α pathway in myeloid cells offers a valuable translational opportunity for developing therapeutics against not only hepatic I/R injury-related conditions, but also other types of inflammatory liver diseases (72).

**Experimental procedures**

**Animals**

Wild-type C57/BL6 mice were purchased from the Experimental Animal Research Center of Hubei Province. Myeloid-specific IRE1 α knockout mice (M Φ KO) were generated by intercrossing floxed Ern1 mice with the lyz2-Cre line as previously described (42). Mice were maintained in individual temperature-controlled ventilated cages with a 12-h light/dark cycle (7:00 AM light on) in a specific-pathogen-free (SPF) facility. All animal experiments were approved by the Animal Care and Use Committee of College of Life Sciences, Wuhan University.

**Hepatic ischemia/reperfusion injury mouse model**

Mice were subjected to a 70% liver warm I/R surgery as described in detail (73). Briefly, upon anesthetization with sodium pentobarbital, male mice at ~8–14 weeks of age were subjected to midline laparotomy to expose the liver. The middle and left portal vein branches were blocked for 60 min using atraumatic clamps to induce partial hepatic ischemia, and then the clamps were removed to allow for 6 h of reperfusion before mice were sacrificed. As a sham control, mice were subjected to the same surgical process except vasculature occlusion.

**Treatment of hepatic I/R injury with chemical inhibitors**

For IRE1 α RNase inhibition, mice were intraperitoneally (i.p.) injected daily with 4 μgC (10 mg per kg body weight; Targetmol, #T6363) or 10% DMSO, 40% PEG300, 5% Tween 80 in saline as vehicle control for 3 days before hepatic I/R surgery was performed. For iNOS inhibition, mice were injected with 1400W (35 mg per kg body weight; Targetmol, #T3491) or 10% DMSO, 40% PEG300, 5% Tween 80 in saline as vehicle control at 1 h prior to hepatic I/R surgery.

**Clodronate depletion of liver-resident macrophages**

For depletion of liver-resident macrophages including KCs, animals were injected through tail vein with clodronate liposomes or control liposomes (200 μl per mouse, LIPOSOMA, #CP005005) at 24 h prior to hepatic I/R surgery.

**Histology, TUNEL analysis, and immunohistochemistry**

Sections of liver tissues were fixed in 10% formalin for paraffin embedding. Paraffin-embedded liver sections were subjected to hematoxylin and eosin staining.
For immunohistochemical analysis, liver tissue sections were permeabilized with blocking buffer (3% bovine serum albumin) for 1 h after antigen retrieval and 3% H₂O₂ incubation. Then, the liver sections were incubated in Ly6G antibodies (1:1000 dilution; Servicebio, #GB11229) overnight at 4 °C. After washing with PBS, samples were incubated with HRP-conjugated secondary antibody (1:1000 dilution; Servicebio, #GB23303) 1 h at 37 °C prior to the incubation with...
**Kupffer cell IRE1α promotes hepatic I/R injury**

Diaminobenzidine Tetrahydrochloride (DAB). Section images of H&E and IHC staining were visualized by a light microscope. Cell death was analyzed using the Dead End Fluorometric Tunel System (Promega, #G3250) according to the manufacturer's instructions. Signals of dead cells were visualized by fluorescence microscopy. Necrotic area, Ly6G+ neutrophils, and Tunel+ cells were quantified using Image J software.

**Serum measurements**

Serum levels of TNFα (ABclonal, #RK00027), IL-1β (ABclonal, #RK00006), CCL-2 (ABclonal, #RK00381), and CXCL-10 (ABclonal, #RK00054) were measured using ELISA kits following manufacturers’ instructions. Serum ALT and AST levels were measured using the Mindray kit (Mindray) on an ABI 7500 system (Applied Biosystems). β-Actin was used as an internal control for normalization. Primers sequences used are as follows:

- **β-Actin** Forward: 5'-AGTGTGACGTGTTACATCGTA-3';
- **β-Actin** Reverse: 5'-GCAGAGCATGAATCTCCTT-3';
- **Xbp1s** Forward: 5'-CTGAGTCCGAATCTAGGTGAC-3;
- **Xbp1s** Reverse: 5'-GTCCTAGGAAATATTCTGCG-3;
- **Erdj4** Forward: 5'-ATAAAGCCCTGATGCTGAG-3;
- **Erdj4** Reverse: 5'-GCCATTGTTAAAGCAGCTGTG-3;
- **Bip** Forward: 5'-ACCTGGGGACCACTATTTCA-3;
- **Bip** Reverse: 5'-ATCGCAATCACAGCCTTC-3;
- **Chop** Forward: 5'-CTGGAGCTGTATGAGGAT-3;
- **Chop** Reverse: 5'-CAGGGTCAAGAGATGAAGGT-3;
- **Atf4** Forward: 5'-CTTTCAGACGTGGGTGTG-3;
- **Atf4** Reverse: 5'-CGCACGGGTAAGAGCCATT-3;
- **Nos2** Forward: 5'-ACATCGAACCCTCAGCTAT-3;
- **Nos2** Reverse: 5'-CAGAGGGGTAGGCTTCTGC-3;
- **Tnfα** Forward: 5'-GAGCTGGAACCTGGCAAGAG-3;
- **Tnfα** Reverse: 5'-ACCGCTTGAGTTCTGGA-3;
- **Il1b** Forward: 5'-GCAACTGTTCCTGACATCT-3;
- **Il1b** Reverse: 5'-ATCTTTTGGTTGGCTCAGCT-3;
- **Ccl2** Forward: 5'-TAAACACCTGGATCGGAACAA-3;
- **Ccl2** Reverse: 5'-GCAATTAGCTTCAGATTTACCGGT-3.

**Quantitative RT–PCR**

Total RNA was isolated from cells or liver tissues using TRIzol reagent (sigma). cDNA was synthesized with M-MLV reverse transcriptase and random hexamer primers (Invitrogen). Quantitative real-time PCR was performed with SYBR Green PCR reagents (Applied Biosystems) on an ABI 7500 system (Applied Biosystems). β-Actin was used as an internal control for normalization. Primers sequences used are as follows:

- **β-Actin** Forward: 5'-AGTGTGACGTGTTACATCGTA-3';
- **β-Actin** Reverse: 5'-GCAGAGCATGAATCTCCTT-3';
- **Xbp1s** Forward: 5'-CTGAGTCCGAATCTAGGTGAC-3;
- **Xbp1s** Reverse: 5'-GTCCTAGGAAATATTCTGCG-3;
- **Erdj4** Forward: 5'-ATAAAGCCCTGATGCTGAG-3;
- **Erdj4** Reverse: 5'-GCCATTGTTAAAGCAGCTGTG-3;
- **Bip** Forward: 5'-ACCTGGGGACCACTATTTCA-3;
- **Bip** Reverse: 5'-ATCGCAATCACAGCCTTC-3;
- **Chop** Forward: 5'-CTGGAGCTGTATGAGGAT-3;
- **Chop** Reverse: 5'-CAGGGTCAAGAGATGAAGGT-3;
- **Atf4** Forward: 5'-CTTTCAGACGTGGGTGTG-3;
- **Atf4** Reverse: 5'-CGCACGGGTAAGAGCCATT-3;
- **Nos2** Forward: 5'-ACATCGAACCCTCAGCTAT-3;
- **Nos2** Reverse: 5'-CAGAGGGGTAGGCTTCTGC-3;
- **Tnfα** Forward: 5'-GAGCTGGAACCTGGCAAGAG-3;
- **Tnfα** Reverse: 5'-ACCGCTTGAGTTCTGGA-3;
- **Il1b** Forward: 5'-GCAACTGTTCCTGACATCT-3;
- **Il1b** Reverse: 5'-ATCTTTTGGTTGGCTCAGCT-3;
- **Ccl2** Forward: 5'-TAAACACCTGGATCGGAACAA-3;
- **Ccl2** Reverse: 5'-GCAATTAGCTTCAGATTTACCGGT-3.

**Statistical analysis**

All data are presented as the mean ± SD. Statistical analysis was performed with unpaired two-tailed Student’s t test or one-way or two-way analysis of variance (ANOVA) followed by Bonferroni’s test using GraphPad Prism 8.0. *p < 0.05 was considered to be statistically significant.

**Data availability**

The data that support the findings of this study are available from the corresponding author upon reasonable request.

**Supporting information**—This article contains supporting information.

**Acknowledgments**—Special thanks to Dr Hongliang Li and Dr Zan Huang at Wuhan University for advice and assistance with the animal I/R injury experiments.

**Author contributions**—J. C., B. S., and Yong Liu conceptualization; X. Z. and S. L. data curation; K. S. formal analysis; J. L. and Yong Liu methodology; Yong Liu project administration; Q. L., K. S., and Yong Liu resources; X. Z., S. L., and Z. W. software; J. C., X. Z., P. C., and J. L. validation; J. C., X. Z., Q. L., B. S., and Yong Liu supervision; J. C., P. C., Yang Li, and Yong Liu funding acquisition; J. C., X. Z., P. C., B. S., and Yong Liu visualization; J. C., X. Z., K. S., and Yong Liu investigation; J. C. and P. C. conceptualization; X. Z. and S. L. resources; X. Z., S. L., and Z. W. software; J. C., X. Z., P. C., and J. L. project administration; Q. L., K. S., and Yong Liu funding acquisition; J. C., X. Z., and P. C. data curation; X. Z. and S. L. writing—original draft preparation; K. S. writing—review and editing; J. L. writing—review and editing; Yong Liu writing—review and editing; J. C., X. Z., and P. C. writing—review and editing; and J. C., X. Z., Q. L., B. S., and Yong Liu visualization.
and H. Z. validation; B. S. and Yong Liu writing—original draft; B. S. and Yong Liu writing—review and editing.

Funding and additional information—This work was supported by grants from the Ministry of Science and Technology of China (National Key R&D Program of China 2018YFA0800700) to Y. L., and from the National Natural Science Foundation of China (No. 31690102, 91857204, 32021003 and 91739303) to Y. L. and J. L. Supported also by Fundamental Research Funds for the Central Universities (2042020KI1056) to Y. L.

Conflict of interest—The authors declare that they have no conflicts of interest with the contents of this article.

Abbreviations—The abbreviations used are: ALT, alanine aminotransferase; AST, aspartate aminotransferase; ATF6, activating transcription factor 6; ER, endoplasmic reticulum; iNOS, inducible nitric oxide synthase; I/R, ischemia/reperfusion; IRE1, inositol-requiring enzyme 1; KC, Kupffer cell; NLRP3, nucleotide-binding domain, leucine-rich repeat containing protein 3; PERK, protein kinase RNA-like endoplasmic reticulum kinase; RIDD, regulated domain, leucine-rich repeat containing protein; ROS, reactive oxygen species; TXNIP, thioredoxin-interacting protein; UPR, unfolded protein response; XBPI, X-box binding protein 1.

References
1. Zhai, Y., Petrowsky, H., Hong, J. C., Busuttil, R. W., and Kupiec-Weglinski, J. W. (2013) Ischaemia-reperfusion injury in liver transplantation—From bench to bedside. Nat. Rev. Gastroenterol. Hepatol. 10, 79–89.
2. Rakic, M., Patrlj, L., Amic, F., Aralica, G., and Grgeurevic, I. (2018) Comparison of hepatoprotective effect from ischemia-reperfusion injury of remote ischemic preconditioning of the liver vs local ischemic preconditioning of the liver during human liver resections. Int. J. Surg. 54, 248–253.
3. Zhang, X. J., Cheng, X., Yan, Z. Z., Fang, J., Wang, X., Wang, W., Liu, Z. Y., Shen, L. J., Zhang, P., Wang, P. X., Liao, R., Ji, Y. X., Wang, J. Y., Tian, S., Zhu, X. Y., et al. (2018) An ALOX12-12-HETE-GPR31 signaling axis is a key mediator of hepatic ischemia-reperfusion injury. Nat. Med. 24, 73–83.
4. Quesnelle, K. M., Bystrom, P. V., and Toledo-Pereyra, L. H. (2015) Molecular responses to ischemia and reperfusion in the liver. Arch. Toxicol. 89, 651–657.
5. Yang, Q., Liu, Y., Shi, Y., Zheng, M., He, J., and Chen, Z. (2013) The role of intracellular high-mobility group box 1 in the early activation of Kupffer cells and the development of Con A-induced acute liver failure. Immunobiology 218, 1284–1292.
6. Huang, H., Chen, H. W., Evankovich, J., Yan, W., Rosborough, B. R., Nace, G. W., Ding, Q., Loughran, P., Beer-Stolz, D., Billiar, T. R., Esmun, C. T., and Tsung, A. (2013) Histones activate the NLRP3 inflammasome in Kupffer cells during sterile inflammatory liver injury. J. Immunol. 191, 2665–2679.
7. Zhai, Y., Busuttil, R. W., and Kupiec-Weglinski, J. W. (2011) Liver ischemia and reperfusion injury: New insights into mechanisms of innate-adaptive immune-mediated tissue inflammation. Am. J. Transpl. 11, 1563–1569.
8. Nakamura, K., Zhang, M., Kagayama, S., Ke, B., Fujii, T., Sosa, R. A., Reed, E. F., Datta, N., Zarrinpas, A., Busuttil, R. W., Araujo, J. A., and Kupiec-Weglinski, J. W. (2017) Macrophage heme oxygenase-1-SIRT1-p53 axis regulates sterile inflammation in liver ischemia-reperfusion injury. J. Hepatol. 67, 1232–1242.
9. Ahmed, O., Robinson, M. W., and O’Farrelly, C. (2021) Inflammatory processes in the liver: Divergent roles in homeostasis and pathology. Cell. Mol. Immunol. 18, 1375–1386.
10. Dixon, L. J., Barnes, M., Tang, H., Pritchard, M. T., and Nagy, L. E. (2013) Kupffer cells in the liver. Compr. Physiol. 3, 785–797.
11. Krenkel, O., and Tacke, F. (2017) Liver macrophages in tissue homeostasis and disease. Nat. Rev. Immunol. 17, 306–321.
12. Jimenez-Castro, M. B., Cornide-Petronio, M. E., Gracia-Sancho, J., and Peralta, C. (2019) Inflammasome-mediated inflammation in liver ischemia-reperfusion injury. Cells 8, 1131.
13. Inoue, Y., Shirasuna, K., Kimura, H., Usui, F., Kawashima, A., Karasawa, T., Tago, K., Dezaki, K., Nishimura, S., Sagara, J., Noda, T., Iwakura, Y., Tsutsui, H., Taniguchi, S., Yanagisawa, K., et al. (2014) NLRP3 regulates neutrophil functions and contributes to hepatic ischemia-reperfusion injury independently of inflammasomes. J. Immunol. 192, 4342–4351.
14. Bogdan, C. (2001) Nitric oxide and the immune response. Nat. Immunol. 2, 907–916.
15. Nathan, C. (1997) Inducible nitric oxide synthase: What difference does it make? J. Clin. Invest. 100, 2417–2423.
16. MacMicking, J., Xie, Q. W., and Nathan, C. (1997) Nitric oxide and macrophage function. Annu. Rev. Immunol. 15, 323–350.
17. Koerber, K., Sass, G., Kiemer, A. K., Vollmar, A. M., and Tieg, G. (2002) In vivo regulation of inducible nitric oxide synthase in immunemediated liver injury in mice. Hepatology 36, 1061–1069.
18. Hines, I. N., Harada, H., Bharwani, S., Pavlick, K. P., Hoffman, J. M., and Grisham, M. B. (2001) Enhanced post-ischemic liver injury in iNOS-deficient mice: A cautionary note. Biochem. Biophys. Res. Commun. 284, 972–976.
19. Hamada, T., Duarte, S., Tsuchihashi, S., Busuttil, R. W., and Coito, A. J. (2009) Inducible nitric oxide synthase deficiency impairs matrix metalloproteinase-9 activity and disrupts leukocyte migration in hepatic ischemia/reperfusion injury. Am. J. Pathol. 174, 2265–2277.
20. Kawachi, S., Hines, I. N., Laroux, F. S., Hoffman, J., Bharwani, S., Gray, L., Leffer, D., and Grisham, M. B. (2000) Nitric oxide synthase and post-ischemic liver injury. Biochem. Biophys. Res. Commun. 276, 851–854.
21. Walter, P., and Ron, D. (2011) The unfolded protein response: From stress pathway to homeostatic regulation. Science 334, 1081–1086.
22. Hetz, C., Zhang, K., and Kaufman, R. J. (2020) Mechanisms, regulation and functions of the unfolded protein response. Nat. Rev. Mol. Cell Biol. 21, 421–438.
23. Schroder, M., and Kaufman, R. J. (2005) The mammalian unfolded protein response. Annu. Rev. Biochem. 74, 739–789.
24. Cox, J. S., Shamoo, C. E., and Walter, P. (1993) Transcriptional induction of genes encoding endoplasmic reticulum resident proteins requires a transmembrane protein kinase. Cell 73, 1197–1206.
25. Hetz, C. (2012) The unfolded protein response: Controlling cell fate decisions under ER stress and beyond. Nat. Rev. Mol. Cell Biol. 13, 89–102.
26. Hetz, C., Martinon, F., Rodriguez, D., and Glimcher, L. H. (2011) The unfolded protein response: Integrating stress signals through the stress sensor IRE1alpha. Physiol. Rev. 91, 1219–1243.
27. Hollien, J., and Weissman, J. S. (2006) Decay of endoplasmic reticulum-localized mRNAs during the unfolded protein response. Science 313, 104–107.
28. Maurel, M., Chevet, E., Tavernier, J., and Gerlo, S. (2014) Getting RIDD out of RNA: IRE1 in cell fate regulation. Trends Biochem. Sci. 39, 245–254.
29. Malhi, H., and Kaufman, R. J. (2011) Endoplasmic reticulum stress in liver disease. J. Hepatol. 54, 795–809.
30. Huang, S., Xing, Y., and Liu, Y. (2019) Emerging roles for the ER stress sensor IRE1alpha in metabolic regulation and disease. J. Biol. Chem. 294, 18726–18741.
31. Hotamisligil, G. S. (2010) Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell 140, 900–917.
32. Hetz, C., and Glimcher, L. H. (2011) Protein homeostasis networks in physiology and disease. Curr. Opin. Cell Biol. 23, 123–125.
33. Liu, X., and Green, R. M. (2019) Endoplasmic reticulum stress and liver diseases. Liver Res. 3, 55–64.
34. Emadali, A., Nguyen, D. T., Rochon, C., Tzimas, G. N., Metrakos, P. P., and Chevet, E. (2005) Distinct endoplasmic reticulum stress responses are triggered during human liver transplantation. J. Pathol. 207, 111–118.
35. Bailly-Maitre, B., Fondevila, C., Kaldas, F., Droin, N., Luciano, F., Ricci, J. E., Croxton, R., Krajewska, M., Zapata, J. M., Kupiec-Weglinski, J. W., Farmer, D., and Reed, J. C. (2006) Cytoprotective gene b-i is required for intrinsic protection from endoplasmic reticulum stress and ischemia-reperfusion injury. Proc. Natl. Acad. Sci. U. S. A. 103, 2809–2814

36. Duvgnejac, J. C., Kozlov, A. V., Zifko, C., Postl, A., Hartl, R. T., Miller, L., Gille, L., Staniek, K., Moldzio, R., Gregor, W., Haindl, S., Behling, T., Redl, H., and Bahrami, S. (2010) Reperfusion does not induce oxidative stress but sustained endoplasmic reticulum stress in livers of rats subjected to traumatic-hemorrhagic shock. Shock 33, 289–298

37. Liu, J., Ren, F., Cheng, Q., Bai, L., Chen, X., Jiang, M., He, Q., and Zhu, Y. (2018) Kupffer cell IRE1 promotes hepatic I/R injury. J. Biol. Chem. 293, 10,153–10,163.
PKA phosphorylation couples hepatic inositol-requiring enzyme 1alpha to glucagon signaling in glucose metabolism. Proc. Natl. Acad. Sci. U. S. A. 108, 15852–15857

Shao, M., Shan, B., Liu, Y., Deng, Y., Yan, C., Wu, Y., Mao, T., Qiu, Y., Zhou, Y., Jiang, S., Jia, W., Li, J., Li, J., Rui, L., Yang, L., et al. (2014) Hepatic IRE1alpha regulates fasting-induced metabolic adaptive programs through the XBP1s-PPARalpha axis signalling. Nat. Commun. 5, 3528

Wu, Y., Shan, B., Dai, J., Xia, Z., Cai, J., Chen, T., Lv, S., Feng, Y., Zheng, L., Wang, Y., Liu, J., Fang, J., Xie, D., Rui, L., Liu, J., et al. (2018) Dual role for inositol-requiring enzyme 1alpha in promoting the development of hepatocellular carcinoma during diet-induced obesity in mice. Hepatology 68, 533–546

Kupffer cell IRE1alpha promotes hepatic I/R injury

Liu, Y., Shao, M., Wu, Y., Yan, C., Jiang, S., Liu, J., Dai, J., Yang, L., Li, J., Jia, W., Rui, L., and Liu, Y. (2015) Role for the endoplasmic reticulum stress sensor IRE1alpha in liver regenerative responses. J. Hepatol. 62, 590–598

Tacke, F. (2017) Targeting hepatic macrophages to treat liver diseases. J. Hepatol. 66, 1300–1312

Yan, Z. Z., Huang, Y. P., Wang, X., Wang, H. P., Ren, F., Tian, R. F., Cheng, X., Cai, J., Zhang, Y., Zhu, X. Y., She, Z. G., Zhang, X. J., Huang, Z., and Li, H. (2019) Integrated omics reveals tollip as an regulator and therapeutic target for hepatic ischemia-reperfusion injury in mice. Hepatology 70, 1750–1769

Bourgognon, M., Klippstein, R., and Al-Jamal, K. T. (2015) Kupffer cell isolation for nanoparticle toxicity testing. J. Vis. Exp. 18, e52989